SBIR/STTR Research Award

Antibody Microarrays for Cancer Diagnostics

Award identifier e1413ed439dee2cca38a5d4e439ed8b072bc0da570bcd343d9838e9f503393f2Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$749,999

Program and phase

SBIR · Phase II

Award year

2006

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
MERRIMACK PHARMACEUTICALS, INC.
Proposal award date
Not reported
Contract end date
Not reported
UEI
Not reported
Solicitation number
PHS2006-2
Topic code
Not reported

Research abstract

DESCRIPTION (provided by applicant): This Phase II proposal follows successful Phase I studies and describes the development, optimization, scale up, and utility testing of an efficient and cost effective technology to produce and purify high quality and affordable customized scFv antibodies for use in multiplex assays such as antibody arrays. The limited quality and number of reagents available for the construction of antibody micro arrays makes them costly to produce and unreliable to use. Polyclonal and hybridoma derived monoclonal antibodies, frequently don't have the characteristics suitable for use in these micro arrays nor are amenable to molecular evolution for higher affinity and the ability to capture native proteins from solution whilst conjugated to the surface of the micro array. This proposal utilizes yeast display technology to identify, develop, and optimize production of antibody molecules that function under the conditions of the micro array assay, incorporate these into micro arrays and further validate these by using solid tumor samples. The first targets we have selected are a series of receptor tyrosine kinases and their cognate ligands that are known to be involved in multiple types of cancer and for which therapeutics are currently either marketed or in development. The development of high quality antibody reagents for use in the construction of micro arrays will have broad implications in making diagnostic and research tools.

Technology keywords

Not reported

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.